Skip to content

Neogen NEOG Net debt / EBITDA

Net debt / EBITDA at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
3.2×-0.2×
Idexx Laboratories logo
Idexx LaboratoriesIDXX
0.2×-0.2×
Zoetis logo
ZoetisZTS
+0.7×
Revvity logo
RevvityRVTY
+1.2×
TEC
Bio-TechneTECH
0.0×
Agilent Technologies logo
Agilent TechnologiesA
0.9×-0.3×

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$1.92B+12.0%
Enterprise value$2.56B+4.4%
P/S2.2×+0.3×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Calculated from Neogen’s reported figures.

Based on the most recent quarter.

The official record: Neogen’s 10-Q, filed October 10, 2024, on SEC EDGAR. View the filing →

Ask your AI about Neogen's net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neogen's net debt / EBITDA?
Neogen (NEOG) reported net debt / EBITDA of 4.8× in Q2 2024.
How has Neogen's net debt / EBITDA changed year-over-year?
Neogen's net debt / EBITDA increased by 8.1% year-over-year, from 4.5× to 4.8×.
What is the long-term trend for Neogen's net debt / EBITDA?
Over 3 years (2021 to 2024), Neogen's net debt / EBITDA has grown at a 76.3% compound annual growth rate (CAGR), from -0.8× to 4.2×.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.